Pharos Energy plc (PHAR)
London Stock Exchange · UK · prices in GBX · close of 27 Oct 2026
Key indicators
| Last close | GBX 29.20 |
|---|---|
| 52-week range | 18.50 – 34.30 |
| Return, 1 month / 3 months | −3.0% / −7.6% |
| Return, 1 year / 3 years | +42.9% / +55.4% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 42 |
| Volatility (1 year) | 47.1% |
| Worst drawdown (1 year) | -18.2% |
| Average daily value traded | 37.52M GBX |
| Dividend yield | 4.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pharos Energy is an oil and gas company that explores for and produces hydrocarbons. It operates producing fields in Egypt and Vietnam, where it works with partners and state oil companies to extract crude oil and natural gas. The company supplies energy commodities to local and international markets. Pharos Energy is headquartered in London and manages a portfolio of onshore and offshore assets, focusing on mature producing fields where it can apply its technical expertise to extend field life and improve recovery.
Pharos Energy plc trades under the code PHAR on the London Stock Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pharos Energy plc (PHAR) trades on the London Stock Exchange in UK. It last closed at GBX 29.20 on 27 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 1,054 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 42.9% and over the last three months it fell 7.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 72 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.8% | ||
| From 52-week high | -12.8% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -7.6% | ||
| 6-month return | 7.5% | ||
| 12-month return, skipping the last month | 47.3% | ||
| Stability (higher is calmer) | 54 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 47.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.2% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 37.52M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 41 · Weak | Dividend is small or irregular. | |
| Dividend yield | 4.6% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.3% |
|---|---|
| 1 month | −3.0% |
| 3 months | −7.6% |
| 6 months | +7.5% |
| 1 year | +42.9% |
| 3 years | +55.4% |
| 5 years | +82.2% |
Signals
| 50-day / 200-day average | 29.72 / 26.84 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.71 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 Jun 2026 | GBP 0.0093 |
| 18 Dec 2025 | GBP 0.0040 |
| 12 Jun 2025 | GBP 0.0085 |
| 19 Dec 2024 | GBP 0.0036 |
| 13 Jun 2024 | GBP 0.0077 |
| 21 Dec 2023 | GBP 0.0033 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.